» Articles » PMID: 2878741

Central Nervous System Effects of Beta-adrenergic-blocking Drugs: the Role of Ancillary Properties

Overview
Journal Circulation
Date 1987 Jan 1
PMID 2878741
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Among the side effects commonly reported with the use of beta-blockers are symptoms related to the central nervous system (CNS). In this study we compared the effects of four beta-blockers with different ancillary properties (atenolol, metoprolol, propranolol, and pindolol) and placebo on objective and subjective measures of CNS function in 30 healthy male subjects. All subjects were randomly assigned to a double-blind, placebo controlled, Latin-square design study in which five 1 week periods of drug or placebo administration were separated by 2 week washout periods. Laboratory evaluations were conducted at the end of each treatment period, and included multistage exercise stress testing; questionnaire assessments of mood state, sexual function, and sleep habits; tests of psychomotor function; and overnight polysomnographic measures of sleep. Significant effects on sleep continuity were observed for each of the lipophilic drugs, as reflected in the number of awakenings (pindolol = 6.4 +/- 5.0; propranolol = 6.3 +/- 3.2; metoprolol = 7.2 +/- 4.7; atenolol = 3.6 +/- 2.9; placebo = 3.9 +/- 2.7) and time of wakefulness (pindolol = 20.6 +/- 27.0 min; propranolol = 15.5 +/- 23.0 min; metoprolol = 19.5 +/- 24.3 min; atenolol = 10.2 +/- 11.6 min; placebo = 9.2 +/- 74.5 min). Only pindolol significantly affected rapid eye movement (REM) sleep time (pindolol = 54.5 +/- 21.9 min; placebo = 74.5 +/- 74.5 min) and REM latency (pindolol = 175.0 +/- 60.7 min; placebo = 95.4 +/- 43.8 min). Subjective reports of sleep similarly indicated increased wakefulness and greater restlessness with lipophilic beta-blockers.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

β-Blockers and risk of neuropsychiatric disorders: A systematic review and meta-analysis.

Eddin L, Preyra R, Ahmadi F, Jafari A, Omrani M, Muanda F Br J Clin Pharmacol. 2024; 91(2):325-337.

PMID: 39658346 PMC: 11773113. DOI: 10.1111/bcp.16361.


Prevalence of cardiovascular drug-related adverse drug reactions consultations in UK primary care: A cross-sectional study.

Insani W, Whittlesea C, Wei L PLoS One. 2024; 19(7):e0307237.

PMID: 39046945 PMC: 11268649. DOI: 10.1371/journal.pone.0307237.


Metoprolol Inhibits Developmental Brain Sterol Biosynthesis in Mice.

Allen L, Mirnics K Biomolecules. 2022; 12(9).

PMID: 36139049 PMC: 9496459. DOI: 10.3390/biom12091211.


Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease.

Archer M, Dogra N, Dovey Z, Ganta T, Jang H, Khusid J Cell Commun Signal. 2021; 19(1):78.

PMID: 34284799 PMC: 8290582. DOI: 10.1186/s12964-021-00755-6.


Neuropsychiatric Consequences of Lipophilic Beta-Blockers.

Cojocariu S, Mastaleru A, Sascau R, Statescu C, Mitu F, Leon-Constantin M Medicina (Kaunas). 2021; 57(2).

PMID: 33572109 PMC: 7914867. DOI: 10.3390/medicina57020155.